tbuckley/cabot-search huggingface dataset:
The value‐for money of preventing and managing periodontitis: Opportunities and challenges
Authors: Madhuri Pattamatta, Iain Chapple, Stefan Listl
Journal: Periodontology 2000 (2024)

Abstract This article gives an overview of the societal and economic aspects of periodontitis and periodontal care. Despite its largely preventable nature, periodontitis is highly prevalent worldwide and imposes a substantial health and economic burden on individuals and society as a whole. The worldwide estimated direct treatment costs and productivity losses due to periodontitis (including for periodontitis‐related tooth loss) amounted to US$ 186 billion and US$ 142 billion in 2019, respectively. The burden of periodontitis is particularly evident in low and disadvantaged populations. Smoking, dietary habits, and presence of systemic diseases along with social and commercial determinants are considered as risk factors for the periodontal diseases. The cost‐effectiveness of preventing and managing periodontitis has been explored in several studies but it has been highlighted that there is scope for improvement in defining the methodology and quality of reporting of such studies. A recent report by The Economist Intelligence Unit examined the cost‐effectiveness of interventions to prevent and manage periodontal diseases, suggesting that prevention of periodontitis through prevention of gingivitis by means of individual home care would be more cost‐efficient than four other examined approaches. Future research in this field is recommended to further decipher the economic burden of periodontitis to society and to assess the value for money of alternative approaches to address periodontitis with particular emphasis on public health preventive strategies and intersectoral care approaches that address the common risk factors of periodontitis and other non‐communicable diseases simultaneously.
Glioma Approval Sets New Course in Pediatric Drug Development
Journal: Cancer Discovery (2024)

The repositioning of shelved assets for pediatric applications presents a promising avenue for advancing therapies for childhood tumors. Tovorafenib, originally intended for adult melanoma, received approval in April as a treatment for pediatric low-grade glioma. This success has spurred hopes within the industry of replicating this achievement with other previously discontinued drug candidates.
Spatial Transcriptomics: A Powerful Tool in Disease Understanding and Drug Discovery
Authors: Junxian Cao, Caifeng Li, Zhao Cui, Shiwen Deng, Tong Lei, Wei Liu, Hongjun Yang, Peng Chen
Journal: Theranostics (2024)

Recent advancements in modern science have provided robust tools for drug discovery. The rapid development of transcriptome sequencing technologies has given rise to single-cell transcriptomics and single-nucleus transcriptomics, increasing the accuracy of sequencing and accelerating the drug discovery process. With the evolution of single-cell transcriptomics, spatial transcriptomics (ST) technology has emerged as a derivative approach. Spatial transcriptomics has emerged as a hot topic in the field of omics research in recent years; it not only provides information on gene expression levels but also offers spatial information on gene expression. This technology has shown tremendous potential in research on disease understanding and drug discovery. In this article, we introduce the analytical strategies of spatial transcriptomics and review its applications in novel target discovery and drug mechanism unravelling. Moreover, we discuss the current challenges and issues in this research field that need to be addressed. In conclusion, spatial transcriptomics offers a new perspective for drug discovery.
Medical voices against Dr Muhammad Abu Salmiya's detention
Authors: Jessica Smith-Amara
Journal: The Lancet (2024)

As a nurse, one of my most concerning patient presentations is one where a patient has urgently sought care and then suddenly gone silent. Right now, that person is Dr Muhammad Abu Salmiya, the Director of the Al Shifa Hospital, Gaza. When his latest Correspondence was published on Nov 26, 2023,1Salmiya MA Gaza hospitals: military siege and bombings.Lancet. 2023; 4022191Summary Full Text Full Text PDF Scopus (1) Google Scholar he had already been arrested and detained by Israeli forces.2The Times of IsraelIDF arrests Gaza's Shifa Hospital head, sends him for questioning as terror suspect.https://www.timesofisrael.com/head-of-gazas-shifa-hospital-said-detained-by-idf-while-evacuating-northern-strip/Date: Nov 23, 2023Date accessed: November 30, 2023Google Scholar, 3Salman A Israel arrests Al-Shifa Hospital director, Hamas-run Gaza Ministry of Health says.https://edition.cnn.com/middleeast/live-news/israel-hamas-was-gaza-news-11-23-23/h_951e2cbb2a9629f50dd1c7af39202bfcDate: Nov 23, 2023Date accessed: November 30, 2023Google Scholar Concerningly, WHO has urged in a statement for his legal and humanitarian rights to be observed during his detention.4WHOJoint UN mission transfers critical patients from Al-Shifa Hospital in Gaza, under intense fighting.https://www.who.int/news/item/24-11-2023-joint-un-mission-transfers-critical-patients-from-al-shifa-hospital-in-gaza--under-intense-fightingDate: Nov 24, 2023Date accessed: November 30, 2023Google Scholar However, I am writing this today because the returning volley of silence between the medical community and Dr Abu Salmiya is perhaps the most frightening of all. Do we live in a time where the most credible members of society, physicians and physician executives, are arrested and detained without international outrage? Where clinicians working in war zones and sharing updates with the world are detained without the medical community applying pressure to those in power? I think not. I suspect this turn of events is largely unknown. I am not a published author. I do not work for a prestigious institution. But I am a nurse. And if I am only allowed to use my voice for those who are silenced in designated US postal codes, I might as well turn in my licence. I declare no competing interests. The Lancet Group takes a neutral position with respect to territorial claims in published text and institutional affiliations.
Targeting cathepsin C ameliorates murine acetaminophen-induced liver injury
Authors: Jessica Raith, Malte Bachmann, Sina Gonther, Hendrik Stülb, Ali A. Aghdassi, Christine T. N. Pham, Heiko Mühl
Journal: Theranostics (2024)

Acetaminophen (APAP) overdosing is a major cause of acute liver failure worldwide and an established model for drug-induced acute liver injury (ALI). While studying gene expression during murine APAP-induced ALI by 3'mRNA sequencing (massive analysis of cDNA ends, MACE), we observed splenic mRNA accumulation encoding for the neutrophil serine proteases cathepsin G, neutrophil elastase, and proteinase-3 - all are hierarchically activated by cathepsin C (CtsC). This, along with increased serum levels of these proteases in diseased mice, concurs with the established phenomenon of myeloid cell mobilization during APAP intoxication.
Actinium-225 targeted alpha particle therapy for prostate cancer
Authors: Anil P. Bidkar, Luann Zerefa, Surekha Yadav, Henry F. VanBrocklin, Robert R. Flavell
Journal: Theranostics (2024)

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa).Actinium-225 ( 225 Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses.The development of radiolabeling techniques involving EDTA, DOTA, DOTPA, and Macropa chelators has laid the groundwork for advancements in this field.At the forefront of clinical trials with 225 Ac in PCa are PSMA-targeted TAT agents, notably [ 225 Ac]Ac-PSMA-617, [ 225 Ac]Ac-PSMA-I&T and [ 225 Ac]Ac-J591.Ongoing investigations spotlight [ 225 Ac]Ac-hu11B6, [ 225 Ac]Ac-YS5, and [ 225 Ac]Ac-SibuDAB, targeting hK2, CD46, and PSMA, respectively.Despite these efforts, hurdles in 225 Ac production, daughter redistribution, and a lack of suitable imaging techniques hinder the development of TAT.To address these challenges and additional advantages, researchers are exploring alpha-emitting isotopes including 227 Th, 223 Ra, 211 At, 213 Bi, 212 Pb or 149 Tb, providing viable alternatives for TAT.
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries
Authors: M Doortje Reijman, Tycho R Tromp, Barbara A Hutten, G Kees Hovingh, Dirk J Blom, Alberico L Catapano, Marina Cuchel, Eldad J Dann, Antonio Gallo, Lisa C Hudgins, Frederick J Raal, Kausik K Ray, Fouzia Sadiq, Handrean Soran, Jaap W Groothoff, Albert Wiegman, D Meeike Kusters
Journal: The Lancet Child & Adolescent Health (2024)
Maternal, prenatal and postnatal risk factors for early child physical abuse: a French nationwide cohort study
Authors: Flora Blangis, Jérôme Drouin, Elise Launay, Sara Miranda, Mahmoud Zureik, Jérémie F. Cohen, Alain Weill, Rosemary Dray-Spira, Martin Chalumeau
Journal: The Lancet Regional Health - Europe (2024)
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Authors: Joël Guigay, Hervé Le Caer, François-Régis Ferrand, Lionel Geoffrois, Esma Saada-Bouzid, Jérôme Fayette, Christian Sire, Didier Cupissol, Emmanuel Blot, Pierre Guillet, Julien Pavillet, Laurence Bozec, Olivier Capitain, Frédéric Rolland, Philippe Debourdeau, Yoann Pointreau, Claire Falandry, Stéphane Lopez, Alexandre Coutte, Thierry Chatellier, Pierre Dalloz, Cécile Ortholan, Cécile Michel, Benjamin Lacas, Nadir Cheurfa, Dominique Schwob, Jean Bourhis, Cécile Mertens, Anne Aupérin
Journal: The Lancet Healthy Longevity (2024)

A standard treatment for fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME trial, few older patients were included. We aimed to evaluate the efficacy and tolerance of an adapted EXTREME regimen in fit, older patients with recurrent or metastatic HNSCC.
Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease
Authors: Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi, Yasuharu Maeda, Rocío Del Amor, Pablo Meseguer, Bisi Bode Kolawole, Ujwala Chaudhari, Antonio Di Sabatino, Silvio Danese, Yuichi Mori, Enrico Grisan, Valery Naranjo, Subrata Ghosh
Journal: The Lancet. Gastroenterology & hepatology (2024)
Tinea pedis, peripheral vascular disease, and male gender are associated with higher odds of onychomycosis in a retrospective case-control study of 1257 onychodystrophy patients
Authors: Eden Axler, Apostolos Katsiaunis, Joseph N. Charla, Jeremy A.W. Gold, Shari R. Lipner
Journal: Journal of the American Academy of Dermatology (2024)
Mitochondrial Sirtuins in Cancer: A Revisited Review from Molecular Mechanisms to Therapeutic Strategies
Authors: Hui Shen, Wei Ma, Yue Hu, Yuan Liu, Yaowen Song, Leilei Fu, Zheng Qin
Journal: Theranostics (2024)

The sirtuin (SIRT) family is well-known as a group of deacetylase enzymes that rely on nicotinamide adenine dinucleotide (NAD
Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling
Authors: Xiaorui Jin, Qianmei Deng, Shuting Ye, Shuting Liu, Yilong Fu, Yingfu Liu, Guoyang Wu, Gaoliang Ouyang, Tiantian Wu
Journal: Theranostics (2024)

Background: Periostin (POSTN) is a critical extracellular matrix protein in various tumor microenvironments.However, the function of POSTN in thyroid cancer progression remains largely unknown.Methods: Postn and Rag1 knock-out mice and orthotopic mouse models were used to determine the role of POSTN on papillary thyroid tumor progression.Immunofluorescence, cell co-culture, fluorescence in situ hybridization, chromatin immunoprecipitation assay, recombinant protein and inhibitor treatment were performed to explore the underlying mechanisms of POSTN-promoted papillary thyroid tumor growth.Results: POSTN is up-regulated in papillary thyroid tumors and negatively correlates with the overall survival of patients with thyroid cancer.Cancer-associated fibroblast (CAF)-derived POSTN promotes papillary thyroid tumor growth in vivo and in vitro.POSTN deficiency in CAFs significantly impairs CAF-promoted papillary thyroid tumor growth.POSTN promotes papillary thyroid tumor cell proliferation and IL-4 expression through integrin-FAK-STAT3 signaling.In turn, tumor cell-derived IL-4 induces the activation of CAFs and stimulates POSTN expression by activating STAT6.We reveal the crucial role of CAF-derived POSTN and tumor cell-derived IL-4 in driving the development of papillary thyroid tumors through the POSTN-integrin-FAK-STAT3-IL-4 pathway in tumor cells and IL-4-STAT6-POSTN signaling in CAFs.Conclusion: Our findings underscore the significance of POSTN and IL-4 as critical molecular mediators in the dynamic interplay between CAFs and tumor cells, ultimately supporting the growth of papillary thyroid tumors.
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of <scp>TRANSFORM‐HF</scp>
Authors: Veraprapas Kittipibul, Robert J. Mentz, Robert M. Clare, Daniel M. Wojdyla, Kevin J. Anstrom, Eric L. Eisenstein, Andrew P. Ambrosy, Parag Goyal, Hal A. Skopicki, Fassil Ketema, Dong‐Yun Kim, Patrice Desvigne‐Nickens, Bertram Pitt, Eric J. Velazquez, Stephen J. Greene
Journal: European Journal of Heart Failure (2024)
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the <scp>DELIVER</scp> trial
Authors: Mats Christian Højbjerg Lassen, John W. Ostrominski, Silvio E. Inzucchi, Brian L. Claggett, Ian Kulac, Pardeep Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Kieran F. Docherty, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Journal: European Journal of Heart Failure (2024)

Aims Type 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical outcomes and treatment effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) vary in relation to background glucose‐lowering therapy (GLT) in this population is uncertain. Methods and results DELIVER randomized patients with HF and left ventricular ejection fraction (LVEF) &gt;40% to dapagliflozin or placebo. The primary outcome was a composite of worsening HF (HF hospitalization or urgent HF visit) or cardiovascular death. In this pre‐specified analysis of participants with T2D, treatment effects were assessed by number and class of background GLT(s). Of 3150 participants with T2D at baseline, 22.9% were on no GLT, 36.5% were treated with 1 GLT, and 40.6% with ≥2 GLTs. During follow‐up (median: 2.3 years), treatment benefits of dapagliflozin (vs. placebo) on the primary outcome were consistent irrespective of the number of background GLTs (0 GLTs: hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50–1.00; 1 GLT: HR 1.04, 95% CI 0.80–1.34; ≥2 GLTs: HR 0.71, 95% CI 0.56–0.90; p interaction = 0.59). Similar findings were observed among participants with (HR 0.73, 95% CI 0.59–0.92) and without background metformin use (HR 0.89, 95% CI 0.72–1.11; p interaction = 0.22) and in participants with (HR 0.89, 95% CI 0.69–1.16) and without background insulin use (HR 0.78, 95% CI 0.65–0.95; p interaction = 0.45). Dapagliflozin was well‐tolerated irrespective of the number of background GLTs. Conclusions Dapagliflozin safely and consistently improved clinical outcomes among individuals with T2D and HF with LVEF &gt;40% irrespective of the number and class of background GLTs, and the benefits were not influenced by concomitant metformin or insulin use. These data bolster contemporary guidelines supporting first‐line SGLT2i among individuals with T2D and HF, irrespective of background GLT.
Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis <i>In Vivo</i> Using Endobronchial Optical Coherence Tomography
Authors: Sarita R. Berigei, Sreyankar Nandy, Satomi Yamamoto, Rebecca A. Raphaely, Amalia DeCoursey, Jaeyul Lee, Amita Sharma, Hugh G. Auchincloss, Henning Gaissert, Michael Lanuti, Harald C. Ott, Uma M. Sachdeva, Cameron D. Wright, Sophia H. Zhao, Robert W. Hallowell, Barry S. Shea, Ashok Muniappan, Colleen M. Keyes, Lida P. Hariri
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Idiopathic pulmonary fibrosis (IPF) affects the subpleural lung but is considered to spare small airways. Micro-computed tomography (micro-CT) studies demonstrated small airway reduction in end-stage IPF explanted lungs, raising questions about small airway involvement in early-stage disease. Endobronchial optical coherence tomography (EB-OCT) is a volumetric imaging modality that detects microscopic features from subpleural to proximal airways.
A culture shift to support public involvement and engagement in research
Authors: Matthias Eberl, Sheena M. Cruickshank
Journal: The Journal of Experimental Medicine (2024)

The need to empower people to understand their health and well-being has never been greater. However, current research culture does not necessarily prioritize public involvement and engagement, and many scientists are left under-equipped to reap its benefits. Here, we outline both the positive need for purposeful public involvement and engagement in biomedical research and major systemic challenges. While some of our examples stem from the UK, we believe the learnings from them have global significance.
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial
Authors: Steven M Kawut, Rui Feng, Susan S. Ellenberg, Roham Zamanian, Todd Bull, Murali Chakinala, Stephen C. Mathai, Anna Hemnes, Grace Lin, Margaret Doyle, Ruth Andrew, Margaret MacLean, Ioannis Stasinopoulos, Eric Austin, Angela DeMichele, Haochang Shou, Jasleen Minhas, Nianfu Song, Jude Moutchia, Corey E Ventetuolo
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Rationale: Inhibition of aromatase with anastrozole reduces pulmonary hypertension in experimental models. Objectives: We aimed to determine whether anastrozole improved the 6-minute-walk distance (6MWD) at 6 months in pulmonary arterial hypertension (PAH). Methods: We performed a randomized, double-blind, placebo-controlled phase II clinical trial of anastrozole in subjects with PAH at seven centers. Eighty-four postmenopausal women with PAH and men with PAH were randomized in a 1:1 ratio to receive anastrozole 1 mg or placebo by mouth daily, stratified by sex using permuted blocks of variable sizes. All subjects and study staff were masked. The primary outcome was the change from baseline in 6MWD at 6 months. By intention-to-treat analysis, we estimated the treatment effect of anastrozole using linear regression models adjusted for sex and baseline 6MWD. Assuming 10% loss to follow-up, we anticipated having 80% power to detect a difference in the change in 6MWD of 22 meters. Measurements and Main Results: Forty-one subjects were randomized to placebo and 43 to anastrozole, and all received the allocated treatment. Three subjects in the placebo group and two in the anastrozole group discontinued the study drug. There was no significant difference in the change in 6MWD at 6 months (placebo-corrected treatment effect, -7.9 m; 95% confidence interval, -32.7 to 16.9; P = 0.53). There was no difference in adverse events between the groups. Conclusions: Anastrozole did not show a significant effect on 6MWD compared with placebo in postmenopausal women with PAH and in men with PAH. Anastrozole was safe and did not have adverse effects. Clinical trial registered with www.clincialtrials.gov (NCT03229499).
Resistant <i>Trichophyton indotineae</i> Dermatophytosis—An Emerging Pandemic, Now in the US
Authors: Toan S. Bui, Kenneth A. Katz
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
What Is the Best Local Therapy for HCC?
Authors: Yuman Fong, Jonathan Kessler
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Even Joy
Authors: Fred H. Reinhart
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal